ClinicalTrials.gg
RecruitingNCT06810635PPPILUpdated Mar 23, 2026

Polyphenol Metabotypes in People With Diabetes Type 2

An observational study in Type 2 Diabetes Mellitus (T2DM), sponsored by University Hospital, Ghent. Recruiting at 2 sites in Belgium. Open to participants aged 40 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by University Hospital, Ghent · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium — 13 open to participants now, 19 under way, 5 of them phase 3. Diabetes Mellitus, Type 2 · Belgium.

Planned enrollment
16th of 18
100 · median 759
Started
2026
with 2 others
Observational
18 of 149
6 open now
Primary completion
2028-11
later than 11 of 18 live
Registered
141st of 149
by date

Among the 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium, this one is the 16th largest by planned enrollment of the 18 observational ones that give a count, is one of 3 that started in 2026, is one of 18 observational ones, reaches primary completion later than 11 of the 18 other live ones, and was the 141st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Diabetes Mellitus, Type 2 with a site in Belgium, or all of them as a file.
02

Study summary

This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • polyphenol
  • transit time
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Flemish T2DM patients and controls from Ghent region.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all participants
  • between 40-85 years
  • age-matched individuals without diabetes
  • between 18.5-30
  • no metabolic syndrome
  • persons with T2DM
  • at leats 2 years of clinical diagnoses of T2DM
  • stable medication use for at least 1 month

Exclusion criteria

Exclusion Criteria:

  • pregnancy of breastfeeding
  • in last month
  • acute use of anti/pre/probiotics
  • start of new drug or dietary supplements
  • major changes in diet
  • major lifestyle changes
  • diseases
  • Gastrointestinal diseases (inflammatory bowel disease)
  • Bariatric surgery
  • Other forms of diabetes (cystic fibrosis/MODY/T1DM)
  • Heart problems ( 3/4) or previous cardiovascular events
  • Liver problems: non-alcohol steatohepatitis (NASH) and cirrhosis
  • Lung problems ( - GOLD 3/4), cystic fibrosis
  • Uncontrolled thyroid function disruption in the past 6 months
  • Intake of coumarin derivatives and direct oral anticoagulant medication
  • Anti-cancer treatment: chemo-/immunotherapy
  • Immonosuppressants (transplant)
  • Antiepileptic drugs
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • T2DM

    persons with type 2 diabetes mellitus

    Dietary Supplement: Oral Polyphenol Challenge Test / PPPIL · Diagnostic Test: fasting blood sample · Diagnostic Test: Fasting urine collection · Diagnostic Test: 24 hours urine collection · Other: Questionnaires · Diagnostic Test: Stool collection · Diagnostic Test: Transit time determination

  • Non diabetic persons

    This cohort is a group without type 2 diabetes or any other chronic illness

    Dietary Supplement: Oral Polyphenol Challenge Test / PPPIL · Diagnostic Test: fasting blood sample · Diagnostic Test: Fasting urine collection · Diagnostic Test: 24 hours urine collection · Other: Questionnaires · Diagnostic Test: Stool collection · Diagnostic Test: Transit time determination

Interventions

  • Dietary supplementOral Polyphenol Challenge Test / PPPIL

    Patients will receive a so-called oral polyphenol challenge test. It is a pill containing a multitude of polyphenol classes (doi: 10.1093/cdn/nzac072.020)

  • Diagnostic testfasting blood sample

    Fasting blood sample will be obtained for determination of markers of metabolic health.

  • Diagnostic testFasting urine collection

    Subjects collect morning urine (or the urine thereafter ) in a separate urine container and write down the time of urine collection for determination of polyphenol metabolites

  • Diagnostic test24 hours urine collection

    Subjects collect urine over the entire 24h. for determination of polyphenol metabolites

  • OtherQuestionnaires

    Questionnaires will be performed to collect information on lifestyle and baseline characteristics: physical activity (IPAQ), sleep (PSQI), drinking and smoking behaviour, drug intake and medical record.

  • Diagnostic testStool collection

    Optional: some subjects collect stool samples to test the capacity of the microbiome to degrade polyphenols with a batch experiment.

  • Diagnostic testTransit time determination

    Subjects take a pill containing 90mg of royal blue dye (E133) together with the polyphenol pill to determine their transit time. When their stool discolours, the subjects notify the researcher.

06

What researchers measure

Primary outcomes

  1. Differences in polyphenol metabolites in morning urine in persons with type 2 diabetes and in healthy controls.

    The study aims to characterize the overall polyphenol metabotype in patients with T2DM compared to age-matched individuals without diabetes. For this purpose we will look at morning urine 24h after ingestion of a polyphenol rich pill.

    Time frame: This will be assessed the morning after ingestion of the pill containing polyphenols

Secondary outcomes

  1. Differences in polyphenol metabolites in 24h urine in persons with type 2 diabetes and in healthy controls.

    For this purpose participants will collect urine over a 24h period

    Time frame: Urine will be collected over a 24h period after ingestion of the polyphenol pill.

  2. Transit time

    Along with the ingestion of the polyphenol pill, people will consume E133, a food colorant that will also color the stool.

    Time frame: baseline

  3. the capacity of the gut microbiome to degrade polyphenols

    By using a batch experiment.

    Time frame: baseline

  4. Metabolic health

    This will be determined on the fasting blood samples

    Time frame: baseline

  5. lifestyle factors and medical history (A)

    physical activity, using the validated IPAQ questionnaire

    Time frame: baseline

  6. lifestyle factors and medical history (B)

    Sleep, using the validated PSQI questionnaire

    Time frame: baseline

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All anonymous data will be made available on request after publication also to other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Nov 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Feb 5, 2025
StartActual
Mar 4, 2026
Primary completionEst.
Nov 2028
CompletionEst.
Dec 2028
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06810635
Collaborators
University Ghent, University of Parma, Universiteit Antwerpen
Responsible party
Sponsor
First posted
Feb 5, 2025
Start date
Mar 4, 2026
Primary completion
Nov 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Mar 23, 2026

Study contacts

Jan Stautemas, PhD
Contact
jan.stautemas@ugent.be
003293328967
Patrick Calders, Professor
Contact
patrick.calders@ugent.be
Bruno Lapauw, Professor
principal investigator · University Hospital, Ghent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion